Akston Biosciences
  • Programs
    • Pipeline
    • Platform
    • Process
  • Company
    • Overview
    • Leadership
    • Facilities
    • Partners
    • Contact
  • Careers
    • Overview
    • Career Opportunities
    • Our Culture
    • Contact
  • News
    • Overview
    • In The News
    • Press Releases
    • Papers

In The News

American Pharmaceutical Review

17 March 2022

Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries

17 March 2022

Stelis Licenses Akston’s AKS-452 Thermostable Protein Subunit COVID Vax

Precision Vaccinations

17 March 2022

2nd Generation COVID-19 Vaccine Available in 130+ Countries

8 February 2022

Easier-To-Produce Room Temperature Covid Shot Shows Promise In Early Clinical Trials

GlobalData

6 January 2022

Akston Biosciences seeks USD 10m–25m raise, plans for further COVID-19 vaccine booster trials

2 December 2021

What will tomorrow’s Covid-19 vaccines be like?

11 November 2021

‘Looking forward to second-gen vaccines,’ says WHO chief: From nasal sprays to multivariant jabs, vaccines in development spur hope of ending the pandemic

1 November 2021

Vaccinating the World: the effort to get COVID vaccines to everyone

29 September 2021

The Next COVID Challenge: Building an Arsenal of Vaccines

7 September 2021

Second-generation vaccines offer a chance to correct flaws in early vaccination campaigns

Posts navigation

« 1 2 3 4 5 »

Akston BioSciences

info@akstonbio.com |

  • Home
  • Company
  • Pipeline
  • Careers
  • Press Releases
  • Contact

©2023 Akston Biosciences Corporation